Omnicell Inc - OMCL STOCK NEWS

Omnicell, Inc. (NASDAQ: OMCL) has launched the IVX Station, an advanced IV compounding robot designed to improve efficiency and patient safety in pharmacy care. This technology enhances throughput speed threefold compared to existing solutions, addressing past reliability issues. Alongside this, the Winter 2022 Release introduces various improvements, including Omnicell One scorecards, a new refrigerated carousel for drug management, and upgraded XT Anesthesia Workstation features. These innovations aim to streamline pharmacy operations amidst regulatory complexities and rising healthcare costs.

Omnicell announced changes to its Board of Directors, revealing that Jim Judson and Bruce Smith will not seek reelection at the 2022 Annual Meeting, reducing the board size to nine members. Mary Garrett has been nominated to join the board, enhancing its expertise in digital transformation and healthcare technology. Garrett's impressive background includes a lengthy tenure at IBM and current board positions at other companies. Additionally, Dan Johnston will retire as Executive VP and Chief Legal Officer. These moves are part of Omnicell's strategy to strengthen leadership and improve healthcare solutions.

Omnicell, a leader in medication management, has entered a 10-year agreement with UMC Health System in Lubbock, Texas, to implement its cloud-based solutions for pharmacy automation and patient engagement. This partnership aims to enhance operational efficiency and patient safety through advanced pharmacy technology.

With UMC's significant demand increase and high uninsured rates in Texas, the solutions are expected to improve health outcomes in underserved communities.

Omnicell's Autonomous Pharmacy vision will drive performance and allow clinicians to focus more on patient care.

Omnicell, Inc. (NASDAQ:OMCL) reported a robust performance in 2021, achieving total revenues of $1.132 billion, a 27% increase from the previous year. Fourth quarter revenues reached $311 million, marking a 25% year-over-year growth. The company ended 2021 with a product backlog of $1.254 billion and completed acquisitions to expand its service offerings. For 2022, Omnicell expects revenues between $1.385 billion and $1.410 billion, with guidance aiming for non-GAAP earnings of $3.75 to $3.95 per share.

Omnicell, Inc. (NASDAQ:OMCL) will release its financial results for Q4 and full-year 2021 on February 14, 2022, after market close. A conference call and webcast to discuss these results will follow at 1:30 p.m. PT the same day. Interested parties can participate by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally. Omnicell focuses on improving pharmacy care delivery through automation and technology, with over 7,000 facilities utilizing its solutions globally.

Omnicell has acquired MarkeTouch Media for $82 million, enhancing its EnlivenHealth division's reach in the retail pharmacy market. The acquisition aims to leverage MarkeTouch's mobile and web-based patient engagement solutions, potentially expanding into specialty pharmacy and pharmacy benefits management sectors. MarkeTouch recorded approximately $14 million in revenue for the year ending October 31, 2021. This move is expected to boost Omnicell's non-GAAP EBITDA and earnings per share immediately.

Omnicell has acquired ReCept Holdings for $100 million, enhancing its Advanced Services portfolio in specialty pharmacy management. The acquisition is projected to boost Omnicell's non-GAAP EBITDA starting Q1 2023, aligning with its strategy to address the complex specialty pharmacy market. ReCept reported annual recurring revenue of $24 million as of September 30, 2021. This addition allows Omnicell to optimize specialty pharmacy programs and improve patient care, further solidifying its position in medication management solutions.

Omnicell announced its strategic acquisition of ReCept Holdings for $100 million, aiming to enhance its Advanced Services portfolio. This acquisition responds to the growing need for effective management of complex medications, which represent over 50% of the U.S. drug spending. ReCept's capabilities in specialty pharmacy management will support Omnicell's vision of an Autonomous Pharmacy. This transaction is expected to close by year-end 2022 and will be accretive to Omnicell's non-GAAP EBITDA in Q1 2023.

Omnicell, Inc. (NASDAQ: OMCL) announced its participation in two upcoming investor conferences. Randall Lipps, Chairman and CEO, along with Scott Seidelmann, Executive VP, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:00 am ET. Additionally, Peter Kuipers, Executive VP and CFO, will appear at the 2021 Stephens Annual Investment Conference on December 3, 2021, at 10:00 am CT in Nashville, TN. Webcasts of both presentations will be accessible on the Omnicell website.